( BERKELEY HEIGHTS N.J.--(BUSINESS WIRE)...)Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR,Health

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that scientists from the company will present results of two preclinical studies with sapacitabine and seliciclib, the company's most advanced drug candidates in clinical development. The results will be reported in two poster presentations during the upcoming Annual Meeting of the American Association for Cancer Research (AACR) taking place at the Los Angeles Convention Center between April 14-18, 2007. Sapacitabine is an orally-available, novel nucleoside analog in Phase I clinical trials in patients with solid and hematological cancers. Seliciclib is the most advanced orally-available, cyclin dependent kinase (CDK) inhibitor in Phase II clinical development in patients with non-small cell lung cancer. Sapacitabine and seliciclib are the lead drug candidates in Cyclacel's pipeline of small molecule cell cycle inhibitors. -0-

The schedule of Cyclacel's presentations is as follows:


       Date          Time (PDT)          Title            Poster

                                                       Number/Session


Monday, April 16    1 PM - 5 PM   Identification of   # 3183

                                   biomarkers to aid  Poster Session

                                   clinical            24, South Hall

                                   development of

                                   sapacitabine

                                   (CYC682), a novel

                                   nucleoside analog


Tuesday, April 17   8 AM - 12 PM  Synergistic         # 4003

                                   combinations       Poster Session

                                   between the oral    31,

                                   CDK inhibitor,     South Hall

                                   seliciclib, and

                                   EGFR inhibitors in

                                   NSCLC

'"/>




Page: 1 2 3 4
Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)